Clinical Trials
21
Active:4
Completed:14
Trial Phases
4 Phases
Phase 2:1
Phase 3:1
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Not Applicable
15 (83.3%)Phase 2
1 (5.6%)Phase 3
1 (5.6%)Phase 4
1 (5.6%)DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Novolimus Eluting Coronary Bioadaptor System
Recruiting
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Elixir Medical Corporation
- Target Recruit Count
- 5000
- Registration Number
- NCT06074549
- Locations
- 🇸🇦
King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter
Not Applicable
Completed
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Elixir Medical Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT05828173
- Locations
- 🇧🇪
ZNA Middelheim, Antwerp, Belgium
🇧🇪Ziekenhuis Oost-Limburg, Campus Sint Jan, Genk, Belgium
🇧🇪Jessa Ziekenhuis, Hasselt, Belgium
DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions
Not Applicable
Active, not recruiting
- Conditions
- Multi Vessel Coronary Artery DiseaseCoronary Artery DiseaseLong Lesions Coronary Artery DiseaseChronic Total Occlusion of Coronary ArteryBifurcation of Coronary Artery
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Elixir Medical Corporation
- Target Recruit Count
- 55
- Registration Number
- NCT05464147
- Locations
- 🇮🇹
Humanitas Research Hospital, Rozzano, Italy
The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
Phase 2
Active, not recruiting
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Elixir Medical Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT05033964
- Locations
- 🇧🇪
ZNA Middelheim, Antwerp, Belgium
🇧🇪AZ Sint Jan Brugge Oostende AV, Brugge, Belgium
🇧🇪Ziekenhuis Oost-Limburg, Campus Sint Jan, Genk, Belgium
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
Not Applicable
Active, not recruiting
- Conditions
- Ischemic Heart DiseaseCoronary Artery Disease
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Elixir Medical Corporation
- Target Recruit Count
- 2400
- Registration Number
- NCT04562805
- Locations
- 🇸🇪
Mälarsjukhuset Eskilstuna, Eskilstuna, Sweden
🇸🇪Hallands sjukhus, Halmstad, Sweden
🇸🇪Helsingborgs lasarett, Helsingborg, Sweden
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found